ArticleDermatology and therapy2023

Efficacy and Safety of Risankizumab for the Treatment of Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Trial.

Alexa B Kimball et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.